Release Date: December 10, 2022
Expiration Date: March 2, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward hematologists and hematologist-oncologists. Pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia B are invited to attend.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the burden of disease for patients with hemophilia B
- Outline the current standard of care for patients with hemophilia B
- Assess clinical trial data for gene therapy for hemophilia B
- Describe models for implementation of gene therapy for hemophilia B into clinical practice
- Apply strategies to select appropriate patients for gene therapy
- Review the role of the multidisciplinary team in the management of patients receiving gene therapy for hemophilia B
Christine L. Kempton, MD, MSc
Professor, Department of Hematology and Medical Oncology and Department of Pediatrics
HoG Inc. Director's Chair in Hemostasis
Director, Benign Hematology Program
Director, Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory
Vice Chair for Faculty Development, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Disclosures: Consultant: BioMarin Pharmaceutical Inc, Genentech, Pfizer Inc, Sanofi US, Spark Therapeutics, Takeda.
Andrew D. Leavitt, MD
Director, Program for Noncancerous Blood Disorders
Co-Director, Hemophilia Treatment Center
University of California, San Francisco
San Francisco, CA
Disclosures: Grant/Research Support: BioMarin Pharmaceutical Inc, Pfizer Inc, Sangamo Therapeutics; Consultant: BioMarin Pharmaceutical Inc, Pfizer, Inc.
Steven Pipe, MD
Professor of Pediatrics and Pathology
Director, Special Coagulation Laboratory
Laurence A. Boxer, MD Research Professor of Pediatrics and Communicable Diseases
Medical Director, Pediatric Hemophilia and Coagulation Disorders Program
University of Michigan
Ann Arbor, MI
Disclosures: Grant/Research Support: Siemens Corporation, YewSavin, Inc; Consultant: Apotex Pharmaceutical Holdings Inc, ASC Therapeutics, Bayer, BioMarin Pharmaceutical Inc, CSL Behring, Freeline Therapeutics Holdings, Genentech, GeneVentiv Therapeutics, HEMA Biologics, LFB, Novo Nordisk, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Roche, Sanofi, Spark Therapeutics, Takeda.
Annette Von Drygalski, MD, PharmD
Director, Hemophilia and Thrombosis Treatment Center
Professor of Medicine
UC San Diego Health
San Diego, CA
Disclosures: Grant/Research Support: Pfizer, Sanofi; Consultant: CSL-Behring, Sanofi, Takeda, Uniqure, Genentech, Regeneron, ASC, Biomarin, Novo Nordisk.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
